Bayer CropScience Ltd
Bayer CropScience Ltd
ChemicalsKey Fundamentals
SmallcapPesticides & AgrochemicalsChemicalsInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Bayer CropScience Ltd insights
46 extracted metrics + investor summaries across FY14–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
5- Company has reduced debt.
- Company is almost debt free.
- Stock is providing a good dividend yield of 3.59%.
- Company has been maintaining a healthy dividend payout of 93.8%
- Company's working capital requirements have reduced from 74.0 days to 56.1 days
Weaknesses
1- The company has delivered a poor sales growth of 5.90% over past five years.
Growth Rate
AI Analysis — Bull vs Bear
Bayer CropScience Ltd is a nearly debt-free MNC subsidiary with a market cap of ₹19,280 Cr, trading at a PE of 28.3x which is below its 10-year historical average of ~39.5x. The company delivers consistent ROE of 23-24% and maintains a high dividend payout of 93.8%, but has struggled with tepid sales growth of ~6% CAGR over five years and the stock has declined 31% in the past year.
- Nearly debt-free balance sheet provides financial resilience and flexibility for future investments
- Consistent ROE of 23-24% over the last 3-5 years indicates efficient capital allocation and strong profitability
- Dividend yield of 3.51% with a payout ratio of 93.8% offers attractive cash returns to shareholders
- Current PE of 28.3x is significantly below the 10-year historical average PE of ~39.5x, suggesting valuation compression
- Working capital days improved from 74.0 to 56.1 days, reflecting better operational efficiency
- Q4 FY25 revenue grew 32% YoY to ₹10,464 million from ₹7,923 million, indicating a recovery trend
- TTM profit growth of 21% outpaces revenue growth of 4%, suggesting margin expansion
- 10-year compounded profit growth of 8% demonstrates long-term earnings consistency backed by MNC parentage from Bayer AG
- Stock has declined 31% over the past year, significantly underperforming the broader market
- Compounded sales growth of only 5.9% over five years and 3% over three years reflects structural demand challenges
- Q2 FY26 revenue declined 10.6% YoY to ₹15,534 million from ₹17,382 million, showing inconsistent quarterly performance
- 10-year stock CAGR of just 1% indicates prolonged wealth destruction on a real-return basis
- PE of 28.3x trades at a premium to the agrochemical sector PE of ~24.8x despite below-sector growth rates
- 3-year compounded profit CAGR of only 1% signals recent earnings stagnation despite long-term track record
- High 93.8% dividend payout leaves limited retained earnings for organic growth or capacity expansion
- Q1 FY25 PBT declined 22% YoY to ₹3,158 million from ₹4,061 million, highlighting earnings volatility
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Rs 22M GST penalty order Jul 15
Bayer CropScience received a Rs 22 Million GST penalty for FY 2020-21 to 2022-23 related to outward supply and input tax credit issues. The company is assessing options to appeal.
- Q1FY27 profit jumps 15% YoY Aug 5
Net profit rose 15% YoY to ₹3,216 million in Q1FY27, driven by strong Agri Care sales and gains from divestment of marketing rights.
- Strong FY26 annual results filed Jul 21
FY26 annual report shows ₹56,750 Million revenue, ₹6,892 Million net profit, and a total dividend of ₹150 per share.
- Bayer AG raises stake to 20.34% Jul 10
Bayer AG acquired 53,54,030 shares from Bayer CropScience AG via block deal on July 8, 2026 at Rs 4,122.30 per share, raising its direct stake to 20.34% through an inter-se promoter transfer.
- New Chairman appointed from Sep 12 Aug 5
Ravi Kirpalani appointed as Additional Independent Director and Chairman effective Sep 12, 2026, succeeding Pankaj Patel.
TL;DR: Bayer CropScience is delivering solid earnings growth with Q1FY27 profit up 15% YoY and a healthy FY26 dividend of ₹150/share, signalling operational strength. The Rs 22M GST penalty is minor relative to company scale and unlikely to materially impact financials. Promoter restructuring (Bayer AG raising direct stake) signals continued parent commitment. The trend is stable-to-improving with earnings momentum intact heading into FY27.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,740 | 1,617 | 955 | 792 | 1,631 | 1,738 | 1,057 | 1,046 | 1,915 | 1,553 | 1,106 | 1,101 | 1,835 |
| Expenses | 1,315 | 1,312 | 827 | 695 | 1,317 | 1,554 | 1,037 | 876 | 1,566 | 1,348 | 989 | 898 | 1,467 |
| Operating Profit | 425 | 305 | 128 | 97 | 314 | 184 | 20 | 171 | 348 | 205 | 117 | 203 | 368 |
| OPM % | 24% | 19% | 13% | 12% | 19% | 11% | 1.9% | 16% | 18% | 13% | 11% | 18% | 20% |
| Other Income | 21 | 16 | 15 | 29 | 27 | 24 | 32 | 37 | 19 | 14 | 16 | 47 | 89 |
| Interest | 8 | 4 | 3 | 5 | 4 | 3 | 4 | 6 | 5 | 4 | 5 | 6 | 4 |
| Depreciation | 31 | 12 | 15 | 16 | 22 | 14 | 15 | 34 | 27 | 14 | 15 | 38 | 50 |
| PBT | 406 | 306 | 124 | 105 | 316 | 190 | 34 | 168 | 335 | 200 | 113 | 206 | 402 |
| Tax % | 19% | 27% | 25% | 9% | 20% | 28% | -2% | 15% | 17% | 24% | 15% | 21% | 20% |
| Net Profit | 328 | 223 | 93 | 96 | 254 | 136 | 34 | 143 | 279 | 153 | 96 | 162 | 322 |
| EPS in Rs | 73.09 | 49.6 | 20.72 | 21.36 | 56.56 | 30.33 | 7.61 | 31.89 | 62.01 | 33.98 | 21.29 | 36.07 | 71.56 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,660 | 2,769 | 2,803 | 2,710 | 3,167 | 3,609 | 4,261 | 4,734 | 5,140 | 5,106 | 5,473 | 5,675 | 5,595 |
| Expenses | 3,144 | 2,334 | 2,389 | 2,300 | 2,684 | 2,883 | 3,450 | 3,923 | 4,216 | 4,147 | 4,783 | 4,801 | 4,702 |
| Operating Profit | 516 | 435 | 414 | 410 | 483 | 726 | 812 | 812 | 924 | 959 | 691 | 874 | 893 |
| OPM % | 14% | 16% | 15% | 15% | 15% | 20% | 19% | 17% | 18% | 19% | 13% | 15% | 16% |
| Other Income | 88 | 82 | 70 | 39 | 51 | -64 | 69 | 112 | 168 | 76 | 118 | 95 | 165 |
| Interest | 5 | 10 | 7 | 11 | 10 | 14 | 13 | 13 | 22 | 20 | 17 | 20 | 19 |
| Depreciation | 25 | 25 | 29 | 33 | 44 | 65 | 74 | 64 | 80 | 74 | 85 | 94 | 117 |
| PBT | 574 | 482 | 448 | 404 | 480 | 583 | 794 | 847 | 990 | 941 | 707 | 855 | 922 |
| Tax % | 33% | 35% | 35% | 26% | 30% | 19% | 38% | 24% | 23% | 21% | 20% | 19% | — |
| Net Profit | 383 | 315 | 291 | 300 | 337 | 474 | 493 | 645 | 758 | 740 | 568 | 689 | 732 |
| EPS in Rs | 105 | 89.13 | 82.31 | 87.41 | 98.18 | 106 | 110 | 144 | 169 | 165 | 126 | 153 | 163 |
| Div. Payout % | 20% | 19% | 21% | 21% | 18% | 24% | 105% | 104% | 77% | 85% | 99% | 98% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 37 | 35 | 35 | 34 | 34 | 45 | 45 | 45 | 45 | 45 | 45 | 45 |
| Reserves | 1,996 | 1,804 | 2,021 | 1,744 | 2,205 | 2,528 | 2,505 | 2,479 | 2,667 | 2,804 | 2,806 | 2,921 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 2 | 26 | 86 | 74 | 47 | 105 | 82 |
| Other Liabilities | 740 | 597 | 769 | 756 | 1,310 | 1,262 | 1,663 | 1,742 | 1,893 | 1,701 | 2,290 | 2,652 |
| Total Liabilities | 2,773 | 2,437 | 2,825 | 2,535 | 3,549 | 3,836 | 4,239 | 4,353 | 4,679 | 4,597 | 5,246 | 5,699 |
| Fixed Assets | 322 | 290 | 342 | 334 | 440 | 468 | 425 | 468 | 462 | 414 | 470 | 458 |
| CWIP | 1 | 17 | 24 | 36 | 47 | 56 | 76 | 98 | 109 | 119 | 119 | 127 |
| Investments | 29 | 68 | 50 | 0 | 0 | 41 | 52 | 38 | 41 | 54 | 35 | 57 |
| Other Assets | 2,422 | 2,062 | 2,410 | 2,164 | 3,062 | 3,270 | 3,686 | 3,749 | 4,066 | 4,010 | 4,622 | 5,056 |
| Total Assets | 2,773 | 2,437 | 2,825 | 2,535 | 3,549 | 3,836 | 4,239 | 4,353 | 4,679 | 4,597 | 5,246 | 5,699 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 200 | 206 | 157 | 121 | 433 | 666 | 687 | 216 | 609 | 952 | 262 | 1,078 |
| Investing | 485 | 16 | -8 | 38 | -113 | -29 | 7 | 64 | 83 | 0 | 86 | 72 |
| Financing | -42 | -590 | -73 | -581 | -158 | -148 | -556 | -703 | -613 | -656 | -619 | -624 |
| Net Cash Flow | 644 | -367 | 76 | -421 | 162 | 489 | 138 | -424 | 79 | 296 | -272 | 527 |
| Free Cash Flow | 297 | 170 | 108 | 80 | 378 | 638 | 656 | 168 | 537 | 912 | 222 | 1,014 |
| CFO/OP | 76 | 86 | 74 | 53 | 132 | 110 | 105 | 59 | 92 | 113 | 61 | 142 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57 | 53 | 72 | 89 | 81 | 73 | 65 | 77 | 69 | 69 | 63 | 72 |
| Inventory Days | 85 | 169 | 178 | 175 | 294 | 206 | 226 | 235 | 268 | 222 | 319 | 289 |
| Days Payable | 40 | 52 | 67 | 67 | 164 | 101 | 142 | 127 | 129 | 87 | 148 | 167 |
| Cash Conversion Cycle | 102 | 171 | 184 | 197 | 211 | 177 | 149 | 185 | 208 | 204 | 234 | 193 |
| Working Capital Days | 53 | 92 | 104 | 134 | 116 | 77 | 61 | 84 | 86 | 78 | 88 | 56 |
| ROCE % | 31% | 25% | 23% | 22% | 25% | 30% | 31% | 31% | 34% | 34% | 25% | 29% |
Documents
Frequently Asked Questions about Bayer CropScience Ltd
What does Bayer CropScience Ltd do?
Where is Bayer CropScience Ltd (BAYERCROP) listed?
Which sector does Bayer CropScience Ltd belong to?
What is the market capitalisation of Bayer CropScience Ltd?
What is the PE ratio of Bayer CropScience Ltd?
What is the 52-week high and low of Bayer CropScience Ltd?
Does Bayer CropScience Ltd pay dividends?
What is the Return on Equity (ROE) of Bayer CropScience Ltd?
How can I research Bayer CropScience Ltd on Tapetide?
Company Information
Bayer CropScience is engaged in Agri Care business which primarily includes manufacture, sale and distribution of insecticides, fungicides, herbicide and various other agrochemical products and corn seeds.[1]